BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 28869177)

  • 1. Correlation of
    Mayoral M; Paredes P; Saco A; Fusté P; Perlaza P; Tapias A; Fernandez-Martinez A; Vidal L; Ordi J; Pavia J; Martinez-Roman S; Lomeña F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):80-86. PubMed ID: 28869177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of (18)F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer.
    Mayoral M; Fernandez-Martinez A; Vidal L; Fuster D; Aya F; Pavia J; Pons F; Lomeña F; Paredes P
    Rev Esp Med Nucl Imagen Mol; 2016; 35(2):88-95. PubMed ID: 26541072
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
    Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    González García B; García Vicente AM; Jiménez Londoño GA; Pena Pardo FJ; Bellón Guardia ME; Talavera Rubio MP; Palomar Muñoz A; Gómez Herrero P; Soriano Castrejón ÁM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(4):233-240. PubMed ID: 28284928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
    Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
    Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [
    Glickman A; Paredes P; Carreras-Diéguez N; Niñerola-Baizán A; Gaba L; Pahisa J; Fusté P; Del Pino M; Díaz-Feijóo B; González-Bosquet E; Agustí N; Sánchez-Izquierdo N; Fuster D; Perissinotti A; Romero I; Fernández-Galán E; Carrasco JL; Gil-Ibáñez B; Torné A
    Eur Radiol; 2022 Apr; 32(4):2200-2208. PubMed ID: 34586465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
    Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N
    Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer.
    Liao S; Lan X; Cao G; Yuan H; Zhang Y
    Clin Nucl Med; 2013 Sep; 38(9):715-20. PubMed ID: 23856825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer.
    Lee JW; Cho A; Lee JH; Yun M; Lee JD; Kim YT; Kang WJ
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1898-906. PubMed ID: 24852188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC).
    Mirili C; Guney IB; Paydas S; Seydaoglu G; Kapukaya TK; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M
    Int J Clin Oncol; 2019 Feb; 24(2):168-178. PubMed ID: 30109543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between
    Zhao J; Wang H
    J Med Imaging Radiat Oncol; 2021 Apr; 65(2):188-194. PubMed ID: 33538120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer.
    Lee M; Lee H; Cheon GJ; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Eur Radiol; 2017 Jan; 27(1):16-23. PubMed ID: 27121932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
    Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of metabolic parameters in distinguishing primary mediastinal lymphomas from thymic epithelial tumors.
    Zhu L; Li X; Wang J; Fu Q; Liu J; Ma W; Xu W; Chen W
    Cancer Biol Med; 2020 May; 17(2):468-477. PubMed ID: 32587782
    [No Abstract]   [Full Text] [Related]  

  • 16. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
    Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
    Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of FDG PET/CT in the Characterization of Sinonasal Neoplasms: Analysis of Standardized Uptake Value Parameters.
    Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z
    AJR Am J Roentgenol; 2018 Dec; 211(6):1354-1360. PubMed ID: 30300005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F-18 FDG PET/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer.
    Gallicchio R; Nardelli A; Venetucci A; Capacchione D; Pelagalli A; Sirignano C; Mainenti P; Pedicini P; Guglielmi G; Storto G
    Eur J Radiol; 2017 Aug; 93():107-113. PubMed ID: 28668403
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Nakajo M; Jinguji M; Shinaji T; Tani A; Nakabeppu Y; Nakajo M; Nakajo A; Natsugoe S; Yoshiura T
    Br J Radiol; 2019 Feb; 92(1094):20180620. PubMed ID: 30273012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.